Crido has advised Poland’s LEK-AM pharmaceutical company on obtaining bank financing and grant support to implement its R&D projects.
According to Crido, “obtaining grant support and commercial financing will enable LEK-AM to carry out the planned R&D projects, which will translate into an increase in the company’s innovativeness and the expansion of its offer with two new medicinal products for the treatment of chronic obstructive pulmonary disease and type 2 diabetes.”
In 2019, Crido advised LEK-AM co-founder Andrzej Wyrzykowski on buying out the company’s other co-founder (as reported by CEE Legal Matters on June 11, 2019).
Crido’s team included Managing Partners Artur Marszalkiewicz and Michal Gwizda, Senior Associate Aleksandra Malolepsza, and Senior Financial Analyst Monika Olak.
Crido did not respond to our inquiry on the matter.